Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 18:2021:1349042.
doi: 10.1155/2021/1349042. eCollection 2021.

Clinical Features and Outcomes of Neuropsychiatric Systemic Lupus Erythematosus in China

Affiliations

Clinical Features and Outcomes of Neuropsychiatric Systemic Lupus Erythematosus in China

Shangzhu Zhang et al. J Immunol Res. .

Abstract

Objective: To identify the clinical characteristics, magnetic resonance imaging (MRI) results, and prognostic factors of neuropsychiatric (NP) systemic lupus erythematosus (SLE; NPSLE) in a relatively large patient series in China.

Methods: Data of patients with NPSLE at Peking Union Medical College Hospital (PUMCH) were collected retrospectively from June 2012 to June 2016. NPSLE patients were compared with 220 non-NPSLE patients. Survival rates were evaluated using the Kaplan-Meier curves, log-rank test, and Cox proportional hazards modeling. Cranial MRI results were also studied.

Results: Of the 194 included patients, sixteen subtypes of NPSLE were identified, and the most common manifestations were seizure (36.6%), acute confusional state (25.3%), and cerebral vascular disease (15.5%). Compared with the non-NPSLE group, NPSLE patients were significantly more likely to have typical lupus symptoms, higher Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) scores (P = 0.002), and positive rate of anti-ribosomal P protein antibodies (P = 0.008). Patients with seizure were more likely to have higher SLEDAI-2K scores and positive anti-β2GP1 than non-NPSLE patients. Sixteen patients died during follow-up. The most common cause of death was infection (37.5%). NPSLE significantly decreased survival rates of SLE patients. Patients with elevated serum creatinine (P = 0.001), hypocomplementemia (P = 0.031), and SLEDAI - 2K scores ≥ 15 (P = 0.014) had shorter survival periods. Eighty-two patients underwent detailed cranial MRI analysis; of these, 50 (61.0%) had abnormal results. Small vessel disease was the most common abnormal finding, followed by inflammatory-like lesions and large vessel disease.

Conclusions: High disease activity and positive rate of anti-ribosomal P protein antibodies may be risk factors for NPSLE. NPSLE decreases survival rates of SLE patients. Renal insufficiency and high disease activity are predictive of poor prognoses for NPSLE patients.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest.

Figures

Figure 1
Figure 1
(a) The overall 1-, 2-, 3-, and 4-year survival rates of NPSLE patients. (b) Survival rates of NPSLE patients and non-NPSLE patients. The survival rate of NPSLE patients is significantly lower than that of non-NPSLE patients (P = 0.001). (c) Survival rates of NPSLE patients with SLEDAI score < 15 and SLEDAI score ≥ 15. The survival rate of NPSLE patients with SLEDAI score < 15 was significantly higher than that of patients with SLEDAI score ≥ 15 (P = 0.014).

Similar articles

Cited by

References

    1. Ahn G. Y., Kim D., Won S., et al. Prevalence, risk factors, and impact on mortality of neuropsychiatric lupus: a prospective, single-center study. Lupus. 2018;27(8):1338–1347. doi: 10.1177/0961203318772021. - DOI - PubMed
    1. Petri M., Orbai A. M., Alarcón G. S., et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis & Rheumatism. 2012;64(8):2677–2686. doi: 10.1002/art.34473. - DOI - PMC - PubMed
    1. Unterman A., Nolte J. E., Boaz M., Abady M., Shoenfeld Y., Zandman-Goddard G. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Seminars in Arthritis and Rheumatism. 2011;41(1):1–11. doi: 10.1016/j.semarthrit.2010.08.001. - DOI - PubMed
    1. Hanly J. G., Su L., Urowitz M. B., et al. Mood disorders in systemic lupus erythematosus: results from an international inception cohort study. Arthritis & Rheumatology. 2015;67(7):1837–1847. doi: 10.1002/art.39111. - DOI - PMC - PubMed
    1. Hanly J. G., Harrison M. J. Management of neuropsychiatric lupus. Best Practice & Research Clinical Rheumatology. 2005;19(5):799–821. doi: 10.1016/j.berh.2005.04.003. - DOI - PubMed

LinkOut - more resources